ARTICLE | Company News
GSK submits albiglutide MAA
March 8, 2013 1:37 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) submitted an MAA to EMA for Eperzan albiglutide to treat Type II diabetes. The pharma submitted an NDA to FDA for the product in January. GSK gained the fusion ...